Material Safety data sheet

Similar documents
Material Safety data sheet

Material Safety Data Sheet

Material Safety data sheet

Safety Data Sheet Gabapentin Tablet

Material Safety Data Sheet:

Material Safety Data Sheet Venlafaxine Extended-Release Capsules

Pack Size: 90,100, 500 and 1000 Tablets per bottle. Strength: 150mg, 200mg and 250mg Pack Size: 60, 90 and 500 Tablets per bottle Revision No.

Strength: 5/10/20/40/80 mg. Pack Size: 30/60/90/500/1000/10000 Tablets per bottle Revision No.: 02

Material Safety Data Sheet

Strength: 1.25/2.5/5/10mg. Pack Size: Bottles 30/90/100/500 Capsules Blisters 100 Capsules Revision No.: 02

Strength: 25/37.5/50/75 and 100 mg Pack Size: 30,60,90,100,500,1000 Tablets per bottle Revision No.: 02

Strength: 500/850/1000mg. Pack Size: 90/100/500/1000 Tablets per bottle Revision No.: 03

MATERIAL SAFETY DATA SHEET

DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES, USP

Pack Size: 20 mg: Blister Pack of 150 tablets (15 x 10 Unit-dose) 40 mg/80 mg: Blister Pack of 250 tablets (25 x 10 Unit-dose)

Strength: 12.5mg/ 25mg/50mg. Pack Size: 100 Tablets per bottle Revision No.: 02

Entecavir Tablets USP

Safety Data Sheet CLOBAZAM TABLETS Strength: 10 mg and 20 mg Pack Size: 100 s Tablets per HDPE Bottle and Carton of 10 Tablets (1 x 10 unit Dose),

Strength: 60 mg and 120 mg Pack Size: 90 and 100 Tablets per bottle Revision No.: 00

Aspartame Material Safety Data Sheet

Topiramate Tablets USP C 12 H 21 NO 8 S. Cadila Healthcare Ltd. Ahmedabad, India

SAFETY DATA SHEET. Oxycodone Hydrochloride (CII) Capsule, 5mg, 100 count bottle NDC

Revision No.: 00. Section 1. Identification Identification of the product Product Name: Budesonide Capsules. Formula: C 25 H 34 O 6 Chemical Name:

Strength: 7.5 mg and 15 mg Pack Size: 90, 100 and 500 Tablets per bottle Revision No.: 02

Safety Data Sheet Ursodiol Tablets, USP

Tramal. (50mg Capsules)

Material Safety Data Sheet (Baclofen)

C17H21NO3 HBr (4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11- methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide

Ampicillin and Sulbactam for Injection, USP

Strength: 200mg. Pack Size: 100/500 Tablets per bottle Revision No.: 02

Safety Data Sheet Duloxetine delayed-release capsules USP

Strength: 60 mg Pack Size: 30/90/100/500 Tablets per bottle Revision No.: 00

SECTION 1. PRODUCT & COMPANY INFORMATION

Strength: 0.5, 1, 2 mg. Pack Size: 30 Tablets per bottle Revision No.: 02

Material Safety Data Sheet

(50mg, 100mg, 150mg & 200mg Sustained Release Tablets)

Safety Data Sheet. 1. Identification. 2. Hazard Identification

TRAZODONE HYDROCHLORIDE TABLETS

Strength: 0.25, 0.5, 1, 2, 3, 4 mg. Pack Size: 30,60,90,100,500,1000 Tablets per bottle Revision No.: 02

SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND COMPANY

MATERIAL SAFETY DATA SHEET Sodium Lignosulfonate

SAFETY DATA SHEET SECTION 1 - IDENTIFICATION

Doxycycline Tablets, USP C 22 H 24 N 2 O 8 H 2 O alpha-6-deoxy-5-oxytetracycline..

Safety Data Sheet. Combi Oven Tablets. Safety Data Sheet 1. IDENTIFICATION OF MATERIAL AND SUPPLIER 2. HAZARDS IDENTIFICATION

MATERIAL SAFETY DATA SHEET

Labetalol Hydrochloride Tablets USP C 19 H 24 N 2 O 3 HCl

MATERIAL SAFETY DATA SHEET

SAFETY DATA SHEET (Globally Harmonized System)

Material Safety Data Sheet SunClean Concrete Tile Cleaner

Safety Data Sheet 1. IDENTIFICATION OF MATERIAL AND SUPPLIER 2. HAZARDS IDENTIFICATION

MATERIAL SAFETY DATA SHEET

SAFETY DATA SHEET. Eye: Eye contact can cause severe irritation, redness, tearing, blurred vision and may cause transient injury to cornea.

material safety data sheet Wasp (Vespula vulgaris / germanica mix) venom FD extract Page: 1/6

For the quantitative determination of human chorionic gonadotropin (hcg) concentration in human serum.

SECTION 1. PRODUCT & COMPANY INFORMATION

MATERIAL SAFETY DATA SHEET (MSDS)

Page 1 of 5. Date of Issue: 13 th September 2016 Soft Serve Machine Cleaner

material safety data sheet

Dental City - VPS Putty SAFETY DATA SHEET

LUPIN LIMITED SAFETY DATA SHEET. Section 1: Identification. Memantine Hydrochloride Extended Release Capsules 7 mg, 14 mg, 21 mg and 28 mg

Material Safety Data Sheet

bis(diphenylphosphino)butane

SAFETY DATA SHEET SECTION 1 - IDENTIFICATION

AMITRIPTYLINE HYDROCHLORIDE TABLETS, USP

1. Identification of the substance/mixture and of the company/undertaking

Material Safety Data Sheet

Penicillin G Procaine in Sesame Oil

MATERIAL SAFETY DATA SHEET MSDS. Upper India Group

SAFETY DATA SHEET 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION 2. HAZARDS IDENTIFICATION

Safety Data Sheet European Format

MATERIAL SAFETY DATA SHEET

SAFETY DATA SHEET. Issue Date: 05/25/2015 Version No: 1 1. Identification

SCRUBBING BUBBLES TOILET CLEANING GEL - CITRUS

Material Safety Data Sheet Sodium bicarbonate MSDS

MATERIAL SAFETY DATA SHEET

: #1 Gray. Safety Data Sheet SECTION 1: IDENTIFICATION SECTION 2: HAZARDS IDENTIFICATION SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

SAFETY DATA SHEET. 1. Identification of the substance or preparation and the company/ undertaking. In vitro diagnostic product; Laboratory chemical

Barium Sulphate Pw21 Product Code: EX-SU0020 Department: inert pigments & fillers C.A.S.:

Alpha-6-deoxy-5-oxytetracycline.

Azithromycin Oral Suspension Finished Product Material Safety Data Sheet

Westco Chemicals, Inc Saticoy Street South - North Hollywood, CA TEL: FAX:

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

SAFETY DATA SHEET (SDS)

MATERIAL SAFETY DATA SHEET

Material Safety Data Sheet MSDS ID: CR-156

LUPIN LIMITED SAFETY DATA SHEET. Section 1: Identification. Mandideep India

: Bicarbonate Concentrate Powder

SAFETY DATA SHEET : KIWI SELECT -SMOOTH LEATHER- SELFSHINE CREAM

MATERIAL SAFETY DATA SHEET

NAME: ZINC OXIDE POWDER USP SDS NO. 3501

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET MSDS No.: 008

SAFETY DATA SHEET (SDS)

Adhere to personal protective measures when giving first aid. First aider: Pay attention to self-protection!

MATERIAL SAFETY DATA SHEET

Transcription:

EMERGENCY OVERVIEW contain Divalproex Sodium and excipients generally considered to be non- toxic and non-hazardous in small quantities and under conditions of normal occupational exposure. Section 1. Identification of the substance Identification of the product Product name: Formula: Chemical Name: Sodium hydrogen bis(2- propylpentanoate) Therapeutic Category treat the patierntwith with complex partial seizures Manufacturer / supplier identification Company: Cadila Healthcare Ltd. Ahmedabad, India Contact for information: Tel.: +91 79 6868100 Fax: +91 79 3750319 Emergency telephone No. Tel.: +91 79 6868100 Section 2. Composition / information on ingredients Component Exposure Limit CAS No. Principle Component : Divalproex sodium 76584-70-8 Inactive Ingredients : Colloidal silicon dioxide 7631-86-9 FD &C blue # 1 Gelatin 9000-70-8 Hydroxypropyl methylcellulose 9004-65-3 Methacrylic acid copolymer dispersion 79-41-4 Microcrystalline cellulose spheres 9004-34-6 Sodium lauryl sulfate 151-21-3 Talc 14807-96-6 Titanium dioxide 13463-67-7 Triethyl citrate 99-11-6 Page 1 of 5

Section 3. Health Hazards Information Dose and Administration Adverse Effects Over Dose Effect Contraindications Pregnancy Comments Pregnancy Category Start at 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day until seizure control or limiting side effects Most common adverse reactions (reported >5%) are thrombocytopenia,) nausea, somnolence, dizziness, vomiting, asthenia, abdominal pain, dyspepsia, diarrhea, increased appetite, tremor, weight gain, weight loss, alopecia, headache, fever, anorexia, constipation, diplopia, ambylopia/blurred vision, ataxia, nystagmus, emotional lability, thinking abnormal, amnesia, flu syndrome, infection, bronchitis, rhinitis, ecchymosis, peripheral edema, insomnia, nervousness, depression, pharyngitis, dyspnea, tinnitus. Over dosage with valproate may result in somnolence, heart block, and deep coma. Fatalities have been reported; however patients have recovered from valproate levels as high as 2120 mcg/ml. Divalproex sodium sprinkle capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction Multi-organ hypersensitivity reactions have been rarely reported in close temporal association to the initiation of valproate therapy in adult and pediatric patients Urea cycle disorders. Use of divalproex sodium during pregnancy can cause congenital malformations including neural tube defects. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Divalproex sodium should be considered for women of childbearing potential only after the risks have been thoroughly discussed with the patient and weighed against the potential benefits of treatment. D Section 4. General Overdose Treatment First aid measures Remove from exposure. Remove contiminated Clothing. Person devloping serious hypersensitivity reaction must receive medical attention In overdose situations, the fraction of drug not bound to protein is high and hemodialysis or tandem hemodialysis plus hemoperfusion may result in significant removal of drug. The benefit of gastric lavage or emesis will vary with the time since ingestion. General supportive measures should be applied with particular attention to the maintenance of adequate urinary output. Naloxone has been reported to reverse the CNS depressant effects. Page 2 of 5

Section 5. Fire fighting measures Flash point Upper Flammable Limit: Auto-Ignition Temperature: Lower Flammable Limit: Extinguishing Media Water Spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and material. Fire and Explosion Hazard This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with the dry material to dissipate the potential build up of static electricity. Fire Fighting Procedure As with all fires, evacuate personnel to a safe area. Fire fighter should use selfcontained breathing equipment and protective clothing. Section 6. Storage Storage / Spill / Disposal Measures Store at 20-25 C (68-77 F) Dispense in a tight, light-resistant container. Spill Response Disposal Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labelled container for disposal. Wash spill site. Dispose the waste in accordance with all applicable Federal, State and local laws. Section 7. Respiratory Protection Exposure controls and personal protection Protection from inhalation is not normally necessary. If ventilation is inadequate or dust is likely to generate, use of suitable dust mask would be appropriate. Skin Protection Eye protection Protective Clothing Skin protection is not normally necessary, however it is good practice to avoid contact with chemical to use suitable gloves when handling. Eye protection is not normally necessary. If concerned wear protective goggles or glasses. Wash hands prior to touching eye and in particular handling contact lenses. Protective clothing is not normally necessary, however it is good practice to use apron. Page 3 of 5

Section 8. Physical and chemical properties Appearance (divalproex sodium coated particles in capsules), 125 mg are white to off-white free flowing pellets filled in size 0 hard gelatin capsules with blue colored cap printed with ZA66 in black ink and white body printed with 125mg in black ink and are supplied as follows: In bottle of 100 capsules In bottle of 1000 capsules In blister pack of 100 unit dose capsules Odour Odourless Melting Point No Data Available Solubility in water No Data Available Vapour density No Data Available Boiling point No Data Available Evaporation rate No Data Available Evaporation rate No Data Available Specific gravity No Data Available Reactivity in water No Data Available Vapour pressure No Data Available % Volatile by volume No Data Available Other information No Data Available Section 9. Physical Hazards Condition to avoid Avoid exposure to extreme heat, light and moisture. Stable Stable under normal ambient and anticipated storage and handling conditions. Decomposition Products No Data Available Hazardous Reaction No data available. Incompatibilities No data available. Page 4 of 5

Section 10. Toxicological information Handling of formulated product is not expected to cause any adverse affects. The data pertains to the ingredient in formulations, rather than this specie formulation. Rare instances of deliberate or accidental overdose have resulted in death. Section 11. Ecological information No data available on Ecotoxicity Section 12. Other information None Date of issue: 17/07/2008 Supersedes edition of: New Edition The information contained herein is based on the state of our knowledge. It Characterises the product with regard to the appropriate safety precautions. It does not represent a guarantee of the properties of the product. Page 5 of 5